Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 CRISPR/Cas9 KO Plasmid (m): sc-418955

Overview

Chrna6 encodes the α6 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), ligand-gated cation channels that modulate membrane excitability and neurotransmitter release in response to acetylcholine and nicotine. α6-containing nAChRs are enriched in dopaminergic and other catecholaminergic circuits, where they regulate calcium influx and shape synaptic signaling and plasticity. Through cholinergic neurotransmission pathways, CHRNA6 contributes to reward-related network activity and stimulus-driven neuromodulation. Genetic and functional variation in CHRNA6 has been linked to altered nicotine responses and neurobehavioral phenotypes, supporting its relevance to addiction biology and dopaminergic circuit dysfunction models.

Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Chrna6 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Chrna6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Chrna6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 protein expression.

This CRISPR knockout system enables efficient generation of Chrna6-deficient cell models for investigation of Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting Chrna6 exon(s) critical for Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple Chrna6 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 CRISPR/Cas9 KO Plasmid (m) and Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Chrna6 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 HDR Plasmid (m) and Nicotinic Acetylcholine Receptor alpha 6/CHRNA6 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Chrna6 homology arms to support homology-directed repair at defined Chrna6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.